Key result
Vasopeptidase inhibitors offer dual NEP and ACE inhibition as a novel cardiovascular therapy.
Why the study?
Membrane-bound zinc-dependent peptidases play a key role in blood pressure regulation, and simultaneous inhibition of NEP and ACE by vasopeptidase inhibitors represents a novel therapeutic approach in hypertension.
Simultaneous inhibition of ACE and NEP by vasopeptidase inhibitors offers a promising therapeutic strategy for managing hypertension and related cardiovascular and renal conditions.
Supports evaluation of vasopeptidase inhibitors for hypertension; leaves open efficacy and safety in prospective trials.
The natriuretic peptide and renin-angiotensin systems are physiological counterparts with opposite roles in the regulation of electrolyte balance and blood pressure. In both systems, membrane-bound, zinc-dependent peptidases play an important role in the inactivation or activation of the system. Angiotensin-converting enzyme (ACE) converts angiotensin I into angiotensin II, and neutral endopeptidase (NEP) degrades the natriuretic peptides. Simultaneous inhibition NEP and ACE by a single molecule (a vasopeptidase inhibitor) is a new therapeutic approach in hypertension. Wider applications for vasopeptidase inhibitors being studied include their role as cardioprotective agents in heart failure, as renoprotective agents in chronic renal failure and diabetic nephropathy, and as vasculoprotective agents in endothelial dysfunction and athersclerosis.
No takes yet. Share an insight, caveat, or question.
Kubota et al. (2002) conducted a review in Hypertension. Vasopeptidase inhibitors was evaluated. Simultaneous inhibition of neutral endopeptidase and angiotensin-converting enzyme by vasopeptidase inhibitors represents a new therapeutic approach for hypertension and other cardiovascular conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: